{
    "clinical_study": {
        "@rank": "168325", 
        "arm_group": {
            "arm_group_label": "Women with estrogen independent advanced breast cancer", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This trial will determine the safety and immune activity of HER-2 pulsed DC1 vaccine in\n      patients with high risk HER-2pos breast cancer with residual disease post neoadjuvant\n      therapy. Subjects will have estrogen independent stage I III breast cancer with residual\n      disease in the breast or axillary nodes post-neoadjuvant chemotherapy. Mammogram, laboratory\n      studies, CT, and leukapheresis will be performed, in addition to vaccine administration."
        }, 
        "brief_title": "Pilot Phase I HER-2 Pulsed-DC Vaccine To Prevent Recurrence For Patients With HER-2 Driven High Risk Invasive Breast Cancer Post Neoadjuvant Chemotherapy", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Estrogen Independent Advanced Breast Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Recurrence"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Women over Age 18 years.\n\n          -  Subjects with estrogen independent (as determined by lack of estrogen receptor\n             expression on primary or residual tumor) stage I III breast cancer with residual\n             disease in the breast or axillary nodes post-neoadjuvant chemotherapy.\n\n          -  Women of childbearing age with a negative pregnancy test documented prior to\n             enrollment.\n\n          -  Subjects with ECOG Performance Status Score of 0 or 1. 5. Subjects willing to use\n             birth control if necessary.\n\n          -  Subjects who have voluntarily signed a written Informed Consent in accordance with\n             institutional policies after its contents have been fully explained to them.\n\n        Exclusion Criteria\n\n          -  Pregnant or lactating females (pregnancy testing to be performed within 7 days prior\n             to administration of first dose of vaccine).\n\n          -  Subjects with positive HIV or hepatitis C at baseline by selfreport.\n\n          -  Subjects with coagulopathies, including thrombocytopenia with platelet count 75,000,\n             INR 1.5 and partial thromboplastin time 50 sec\n\n          -  Subjects with major cardiac illness or MUGA 50% EF.\n\n          -  Subjects with pre-existing medical illnesses or medications which might interfere\n             with the study as determined by PI.\n\n          -  Subjects with laboratory tests reflecting \u00ac grade 1 toxicity by NCI CTC version 3.0\n             including CBC, liver function tests, urinalysis, EKG if cannot be corrected on repeat\n             test in 7 days."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02110199", 
            "org_study_id": "UPCC 26113"
        }, 
        "intervention": {
            "arm_group_label": "Women with estrogen independent advanced breast cancer", 
            "intervention_name": "HER-2 pulsed DC1 vaccine", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 9, 2014", 
        "location": {
            "contact": {
                "email": "PennCancerTrials@emergingmed.com", 
                "last_name": "Brian Czerniecki, MD, phD", 
                "phone": "855-216-0098"
            }, 
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19104"
                }, 
                "name": "Abramson Cancer Center of the University of Pennsylvania"
            }, 
            "investigator": {
                "last_name": "Brian Czerniecki, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Pilot Phase I HER-2 Pulsed-DC Vaccine To Prevent Recurrence For Patients With HER-2 Driven High Risk Invasive Breast Cancer Post Neoadjuvant Chemotherapy", 
        "overall_contact": {
            "email": "PennCancerTrials@emergingmed.com", 
            "last_name": "Brian Czerniecki, MD, PhD", 
            "phone": "855-216-0098"
        }, 
        "overall_official": {
            "affiliation": "Abramson Cancer Center of the University of Pennsylvania", 
            "last_name": "Brian Czerniecki, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02110199"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Abramson Cancer Center of the University of Pennsylvania", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Abramson Cancer Center of the University of Pennsylvania", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}